New York State Teachers Retirement System Has $1.09 Million Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

New York State Teachers Retirement System cut its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 67,176 shares of the medical equipment provider’s stock after selling 1,894 shares during the quarter. New York State Teachers Retirement System’s holdings in BioLife Solutions were worth $1,092,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Point72 Hong Kong Ltd acquired a new stake in BioLife Solutions in the first quarter valued at about $36,000. Cubist Systematic Strategies LLC acquired a new stake in BioLife Solutions in the first quarter valued at about $36,000. Lazard Asset Management LLC acquired a new stake in BioLife Solutions in the first quarter valued at about $45,000. Ancora Advisors LLC acquired a new stake in BioLife Solutions in the first quarter valued at about $90,000. Finally, Tower Research Capital LLC TRC boosted its stake in shares of BioLife Solutions by 246.5% during the third quarter. Tower Research Capital LLC TRC now owns 3,929 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 2,795 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group started coverage on BioLife Solutions in a research note on Thursday, April 4th. They set a “buy” rating and a $22.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and a consensus price target of $23.40.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $15.14 on Thursday. The business’s 50-day moving average price is $17.55 and its 200-day moving average price is $15.32. BioLife Solutions, Inc. has a 12 month low of $8.92 and a 12 month high of $24.50. The firm has a market capitalization of $685.84 million, a price-to-earnings ratio of -9.96 and a beta of 1.67. The company has a current ratio of 2.86, a quick ratio of 1.83 and a debt-to-equity ratio of 0.06.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, February 29th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. BioLife Solutions had a negative return on equity of 13.36% and a negative net margin of 46.37%. The company had revenue of $32.73 million during the quarter, compared to the consensus estimate of $32.70 million. Equities research analysts forecast that BioLife Solutions, Inc. will post -0.6 EPS for the current year.

Insider Transactions at BioLife Solutions

In other news, CEO Greef Roderick De sold 2,642 shares of the firm’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $16.76, for a total transaction of $44,279.92. Following the completion of the transaction, the chief executive officer now directly owns 439,897 shares in the company, valued at $7,372,673.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Greef Roderick De sold 2,642 shares of the firm’s stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $16.76, for a total transaction of $44,279.92. Following the completion of the transaction, the chief executive officer now directly owns 439,897 shares in the company, valued at $7,372,673.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Troy Wichterman sold 2,419 shares of BioLife Solutions stock in a transaction that occurred on Friday, January 19th. The stock was sold at an average price of $16.76, for a total value of $40,542.44. Following the completion of the sale, the chief financial officer now owns 64,920 shares of the company’s stock, valued at $1,088,059.20. The disclosure for this sale can be found here. Insiders sold 32,419 shares of company stock worth $550,058 over the last ninety days. 2.70% of the stock is owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.